Randal S. Olshefski, MD :: Nationwide Children’s Hospital, Columbus, Ohio

Randal S. Olshefski, MD

Randal S. Olshefski, MD Best Doctors 2011-2012

Contact Information

Hematology & Oncology
700 Children's Dr
Columbus, OH 43205 [ map ]
PH: (614) 722-3550
FX: (614) 722-3369

Location Information for Patients

Main Campus


Dr. Olshefski is the medical director of the multi-disciplinary Cancer Survivorship clinic at Nationwide Children’s Hospital. His clinical interests include the long-term outcome of childhood cancer survivors, focusing on late effects of treatment. Dr. Olshefski also has an interest in the treatment of patients with Langerhans cell histiocytosis (LCH) and is a member of the Neuro-Oncology team. As Section Chief, Dr. Olshefski represents the Division of Hematology/Oncology/BMT in the numerous Quality and Patient-Safety initiatives that touch patients with cancer and blood disorders.


  • Male

Languages Spoken:

  • English

Education and Training

Medical School

  • University of Pittsburgh School of Medicine
    Date Completed: 05/23/1988


  • Nationwide Children's Hospital
    Date Completed: 06/30/1989


  • Nationwide Children's Hospital
    Date Completed: 06/30/1991


  • Children's National Medical Center
    Date Completed: 06/30/1994


  • Children's National Medical Center
    Date Completed: 06/30/1995


  • Pediatrics


  • Hematology & Oncology


  • Pediatric Hematology Oncology

Date of Appointment at Nationwide Children’s Hospital:

  • 01/22/1998


  • Lehmann,Vicky; Hagedoorn,Mariet; Gerhardt,Cynthia,A; Fults,Marci; Olshefski,Randal,S; Sanderman,Robbert; Tuinman,Marrit,A. 2016. Body issues, sexual satisfaction, and relationship status satisfaction in long-term childhood cancer survivors and healthy controls.  PSYCHO-ONCOLOGY. Vol. 25, no. 2. (February): 210-216.
  • Agrawal,Caitlin; Guthrie,Lory; Sturm,Mollie,S; Stanek,Joseph; Martin,Laura; Henwood-Finley,Maria; Aldrink,Jennifer,H; Olshefski,Randal; O'Brien,Sarah,H. 2016. Comparison of Thyroid Nodule Prevalence by Ultrasound in Childhood Cancer Survivors With and Without Thyroid Radiation Exposure.  Journal of pediatric hematology/oncology. Vol. 38, no. 1. (January): 43-48.
  • Forero-Torres,Andres; Bartlett,Nancy,L; Berryman,Robert,B; Chen,Robert; Matous,Jeffrey,V; Fanale,Michelle,A; O'Connor,Owen,A; Olshefski,Randal; Smith,Scott,E; Huebner,Dirk; Levine,Pamela,L; Grove,Laurie,E; Gopal,Ajay,K. 2015. Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.  LEUKEMIA & LYMPHOMA. Vol. 56, no. 4. (April): 1151-1153.
  • Walston,Steve; Hamstra,Daniel,A; Oh,Kevin; Woods,Gary; Guiou,Michael; Olshefski,Randal,S; Chakravarti,Arnab; Williams,Terence,M. 2015. A multi-institutional experience in pediatric high-grade glioma.  Frontiers in oncology. Vol. 5, no. January: e28.
  • Saha,Aniket; Salley,Christina,G; Saigal,Preeti; Rolnitzky,Linda; Goldberg,Judith; Scott,Suzanne; Olshefski,Randal; Hukin,Juliette; Sands,Stephen,A; Finlay,Jonathan; Gardner,Sharon,L. 2014. Late Effects in Survivors of Childhood CNS Tumors Treated on Head Start I and II Protocols.  PEDIATRIC BLOOD & CANCER. Vol. 61, no. 9. (September): 1644-1672.
  • Dorris,Kathleen; Sobo,Matthew; Onar-Thomas,Arzu; Panditharatna,Eshini; Stevenson,Charles,B; Gardner,Sharon,L; DeWire,Mariko,D; Pierson,Christopher,R; Olshefski,Randal; Rempel,Sandra,A; Goldman,Stewart; Miles,Lili; Fouladi,Maryam; Drissi,Rachid. 2014. Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas.  JOURNAL OF NEURO-ONCOLOGY. Vol. 117, no. 1. (March): 67-76.
  • Arnold,Michael,A; Stallings-Archer,Kandi; Marlin,Evan; Grondin,Ronald; Olshefski,Randal; Biegel,Jaclyn,A; Pierson,Christopher,R. 2013. Cribriform Neuroepithelial Tumor Arising in the Lateral Ventricle.  PEDIATRIC AND DEVELOPMENTAL PATHOLOGY. Vol. 16, no. 4. (July): 301-307.
  • Venkatramani,Rajkumar; Ji,Lingyun; Lasky,Joseph; Haley,Kelley; Judkins,Alexander; Zhou,Shengmei; Sposto,Richard; Olshefski,Randal; Garvin,James; Tekautz,Tanya; Kennedy,Gloria; Rassekh,Shahrad,Rod; Moore,Theodore; Gardner,Sharon; Allen,Jeffrey; Shore,Richard; Moertel,Christopher; Atlas,Mark; Dhall,Girish; Finlay,Jonathan. 2013. Outcome of infants and young children with newly diagnosed ependymoma treated on the "Head Start" III prospective clinical trial.  JOURNAL OF NEURO-ONCOLOGY. Vol. 113, no. 2. (June): 285-291.
  • Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, Carides AD, Taylor A, Devandry S, Valentine J, Evans JK, Oxenius BAdolescent Aprepitant in Cancer Study Group (Adamson PC, Bagatell R, Boklan J, Drachtman RA, Hamre MR, Holdsworth MT, Little M, Olshefski R, Petrilli A, Weinstein JL). 2009. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability.  Pediatr Blood Cancer.. Vol. 52, no. 2. (January): 242-247.
  • Termuhlen AM, Klopfenstein K, Olshefski R, Rosselet R, Yeager ND, Soni S, Gross TG. 2008. Mobilization of PML-RARA negative blood stem cells and salvage with autologous peripheral blood stem cell transplantation in children with relapsed acute promyelocytic leukemia.  Pediatr Blood Cancer.. Vol. 51, no. 4. (October): 521-524.
  • Fangusao J, Finlay J, Sposto R, Ji L, Saly M, Zacharoulis S, Asgharzadeh S, Abromowitch M, Olshefski R, Halpern S, Dubowy R, Comito M, Diez B, Kellie S, Hukin J, Rosenblum M, Dunkel I, Miller D, Allen J, S Gardner. 2008. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience.  Pediatr Blood Cancer. Vol. 50, no. January: 312-318.
  • Altura RA, Olshefski RS, Jiang Y, and BR Bou´e. 2003. Nuclear expression of Survivin in pediatric ependymomas and choroids plexus tumors correlates with morphologic tumor grade.  British J. Cancer. Vol. 89, no. January: 1743-1749.
  • Binkovitz L, Olshefski R, and B Adler. 2003. Coincidence FDG-PET in the evaluation of Langerhans’ cell histiocytosis: preliminary findings.  Pediatr Radiol. Vol. 33, no. January: 598-602.
  • Olshefski,R,S; Ladisch,S. 2001. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity.  INTERNATIONAL JOURNAL OF CANCER. Vol. 93, no. 1. (July): 131-138.
  • Olshefski R and S. Ladisch. 2001. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity.  Int. J. Cancer. Vol. 93, no. January: 131-138.
  • Blanchong C, Olshefski R, and S. Kahwash. 2001. Large granular lymphocyte leukemia: Case report of chronic neutropenia and rheumatoid arthritis-like symptoms in a child.  Pediatr Dev Pathol.. Vol. 3, no. January: 94-99.
  • Robinson R, Nahata M, and R. Olshefski. 2000. Syncope associated with concurrent amitripyline and fluconazole therapy.  Annals Pharmacother. Vol. 34, no. January: 1406-1408.
  • Olshefski,R; Ladisch,S. 1998. Synthesis, shedding, and intercellular transfer of human medulloblastoma gangliosides: Abrogation by a new inhibitor of glucosylceramide synthase.  JOURNAL OF NEUROCHEMISTRY. Vol. 70, no. 2. (February): 467-472.
  • Olshefski, R and S. Ladisch:. 1998. Synthesis, shedding,and intercellular transfer of human medulloblastoma gangliosides: Abrogation by a new inhibitor of glucosylceramide synthase.  J. Neurochem. Vol. 70, no. January: 467-472.
  • Olshefski,R; Taylor,B; Heitger,A; Hasegawa,A; Ladisch,S. 1996. Induction of programmed cell death and immunosuppression by exogenous sphingolipids are separate processes.  EUROPEAN JOURNAL OF BIOCHEMISTRY. Vol. 241, no. 1. (October): 47-55.
  • Ivy,S,P; Olshefski,R,S; Taylor,B,J; Patel,K,M; Reaman,G,H. 1996. Correlation of P-glycoprotein expression and function in childhood acute leukemia: A children's cancer group study.  BLOOD. Vol. 88, no. 1. (July): 309-318.
  • Olshefski,R; Ladisch,S. 1996. Intercellular transfer of shed tumor cell gangliosides.  FEBS LETTERS. Vol. 386, no. 1. (May): 11-14.
  • Olshefski R, Taylor B, Heitger A, Hasagawa A, Ladisch S:. 1996. Induction of programmed cell death and immunosuppression by sphingolipids are separate processes.  Eur. J. Biochem. Vol. 241, no. January: 47-55.
  • Olshefski R and Ladisch S:. 1996. Intercellular transfer of shed tumor gangliosides.  FEBS Lett. Vol. 386, no. January: 11-14.
  • Ivy SP, Olshefski R, Taylor B, Patel K, and Reaman G. 1996. Correlation of P-glycoprotein expression and function in childhood acute leukemia.  Blood. Vol. 88, no. January: 309-318.
  • Hrushesky WJM, Berestka JS, von Roemeling R, Olshefski R, Langevin TR, Potish RA, Delaney JP, Ellefson M, Schwartz S:. 1988. Methylene blue protects intestinal mucosa from free radical-mediated sublethal radiation damage.  Free Radical Biology and Medicine. Vol. 5, no. January: 207-213.
  • Skubitz KM, Wick MR, Skubitz AP, Langevin TR, Olshefski RS, von Roemeling R, Southern RB, Hrushesky WJM:. 1986. Timing of Amphotericin B therapy is a critical determinant of toxicity. In: Reinberg A, Smolensky M, Labrecque G (eds).  Annual Review of Chronopharmacology, New York: Pergamon Press,. Vol. 3, no. January: 183-186.
  • Von Roemeling R, Olshefski R, Lagevin T, Berestka J, Reusch JJ, Reusch JE, Lakatua D, Wick MR, Hrushesky WJM:. 1986. Cisplatin chronotherapy and disulfiram rescue reduce toxicity without interfering with anticancer activity: Animal findings and preliminary clinical experiences.  Chronobiology International,. Vol. 3, no. January: 55-64.
  • Hrushesky W.J.M, Olshefski R, Wood P, Meshnick S, Babson J, Woods W, and Eaton JW. 1985. Methylene Blue Ameliorates Doxorubicin Toxicity. In Proceedings of the 4th International Conference on Superoxide and Superoxide Dismutase. In: Giuseppe Rotilio (Ed) Superoxide and Superoxide Dismutase in Chemistry, Biology, and Medicine. Amsterdam New York Oxford. Elsevier Science Publishers. 642-646 (1985).
  • Hrushesky WJM, Olshefski R, Wood P, Eaton J, Meshnik S:. 1985. Modifying intracellular redox balance: An approach to improving therapeutic index.  Lancet,. Vol. 8428, no. March: 565-567.

NEXT Consortium

Now children everywhere can have faster access to our discoveries and the most advanced blood disorder and cancer treatments possible.

Learn More About the NEXT Consortium »

Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000